Abstract:This prospective study compares 3 different consecutive treatment protocols of gastroduodenal hemorrhage. Three hundred sixty-one patients underwent emergency endoscopy as the basis for further treatment. Clinical and endoscopic findings, such as site and type of the bleeding source, bleeding activity and intensity, age, and concomitant diseases of the patient were scored between 0 and 6 points, the higher number indicating a higher risk. The mean values of the total score of the 7 risk factors were comparable… Show more
“…With rebleeding the success of endoscopic haemostatic treatment drops from 90% with the initial bleeding to 50% (16). Most of the ulcers that rebled were localized in the posterior duodenal bulb or high in the lesser curvature of the stomach (32,(64)(65)(66). The failure to achieve permanent haemostasis in these ulcers can be partly explained from technical problems in positioning the endoscope for optimal injection or thermal therapy in these regions (65,66).…”
Section: Mechanism and Efficacy Of Endoscopic Haemostasismentioning
Kolkman JJ, Meuwissen SGM. A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Gastroenterol 1996;31 Suppl 218: 16-25.The majority of patients presenting with acute upper gastrointestinal haemorrhage bleed from peptic diseases: erosive gastritis and duodenal or gastric ulcers. Early gastroscopy is essential in order to reach a diagnosis, assess the prognosis, and institute appropriate therapy. In a meta-analysis it was shown that H2antagonists significantly reduced mortality. However, two large, prospective and placebo-controlled studies with famotidine and omeprazole failed to show reduction of rebleeding or death. The value of endoscopic haemostatic therapy in patients with high-risk peptic ulcers (active bleeding and non-bleeding visible vessel) has been firmly established with 75% decrease in rebleeding and operation rate, and a 40% reduction in mortality. Risk factors for an adverse outcome are: elderly patients, concomitant diseases and large ulcers in the posterior duodenal bulb or on the lesser curvature. The mortality for emergency surgery in upper GI bleeding is still 10-50%. The mortality of elective operations is less than 2%. Some studies have reduced mortality by avoiding emergency surgery through early elective surgery in high-risk patients.
“…With rebleeding the success of endoscopic haemostatic treatment drops from 90% with the initial bleeding to 50% (16). Most of the ulcers that rebled were localized in the posterior duodenal bulb or high in the lesser curvature of the stomach (32,(64)(65)(66). The failure to achieve permanent haemostasis in these ulcers can be partly explained from technical problems in positioning the endoscope for optimal injection or thermal therapy in these regions (65,66).…”
Section: Mechanism and Efficacy Of Endoscopic Haemostasismentioning
Kolkman JJ, Meuwissen SGM. A review on treatment of bleeding peptic ulcer: a collaborative task of gastroenterologist and surgeon. Scand J Gastroenterol 1996;31 Suppl 218: 16-25.The majority of patients presenting with acute upper gastrointestinal haemorrhage bleed from peptic diseases: erosive gastritis and duodenal or gastric ulcers. Early gastroscopy is essential in order to reach a diagnosis, assess the prognosis, and institute appropriate therapy. In a meta-analysis it was shown that H2antagonists significantly reduced mortality. However, two large, prospective and placebo-controlled studies with famotidine and omeprazole failed to show reduction of rebleeding or death. The value of endoscopic haemostatic therapy in patients with high-risk peptic ulcers (active bleeding and non-bleeding visible vessel) has been firmly established with 75% decrease in rebleeding and operation rate, and a 40% reduction in mortality. Risk factors for an adverse outcome are: elderly patients, concomitant diseases and large ulcers in the posterior duodenal bulb or on the lesser curvature. The mortality for emergency surgery in upper GI bleeding is still 10-50%. The mortality of elective operations is less than 2%. Some studies have reduced mortality by avoiding emergency surgery through early elective surgery in high-risk patients.
“…Tab. 2; [20,33,38,41,42,43,46,55] ne konservative Therapie versucht werden kann [11,28]. Wird später als 12 h nach dem Eintritt und der Persistenz klinischer Symptome operiert, so verschlechtern sich die Resultate deutlich [10, 11,15,50,54].…”
Ulcer surgery today concentrates on the complications of chronic ulcer disease, especially ulcer perforation and endoscopically uncontrollable ulcer bleeding. In this case the laparoscopic or open closure of the gastroduodenal defect or local hemostasis of the bleeding ulcer by laparotomy are the main aims of surgery. Elective operations due to recurrent gastric or duodenal ulcers have become rare. An indication for gastric ulcer resistant to conservative therapy could be persisting suspicion of malignancy whereas in duodenal ulcer gastric outlet obstruction represents a reason for surgery. If these indications are confirmed the classic procedures of gastric resection like Billroth I and Billroth II are performed whereas vagotomy is no longer used. Altogether ulcer surgery has become very safe although it is practiced quite rarely.
“…Early elective surgery in patients considered to be at high risk after initial endoscopic hemostasis was shown by Pimpl et al to reduce the overall mortality rate from 11.2 to 7.1%. 42 A recent prospective randomized trial from a group in Hong Kong compared the outcome after endoscopic retreatment with that of surgery for patients who rebled after initial endoscopic hemostasis. 43 Of 92 patients with rebleeding after endoscopic hemostasis, 48 were randomized to receive endoscopic retreatment and 44 to surgery.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.